No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients by Sarrazin, Christoph, Cooper, Curtis L., Manns, Michael P., Reddy, K. Rajender, Kowdley, Kris V., Roberts, Stuart K., Dvory-Sobol, Hadas, Svarovskia, Evguenia, Martin, Ross, Camus, Gregory, Doehle, Brian P., Stamm, Luisa M., Hyland, Robert H., Brainard, Diana M., Mo, Hongmei, Gordon, Stuart C., Bourliere, Marc, Zeuzem, Stefan, Flamm, Steven L.

Get full text